Results 61 to 70 of about 217,476 (395)

Biomarkers in pancreatic ductal adenocarcinoma

Clinical and Translational Oncology, 2017
Pancreatic ductal adenocarcinoma (PDAC) is currently the third most frequent form of malignancy. The role of biomarkers in the diagnostic and therapeutic strategy of cancer is constantly expanding. Translational research is already changing paradigms in tumours encompassing from early diagnosis to precision medicine in advanced disease.
J. Gallego, C. López, R. Pazo-Cid, F. López-Ríos, A. Carrato   +4 more
openaire   +3 more sources

Contribution of galectin-1, a glycan-binding protein, to gastrointestinal tumor progression [PDF]

, 2017
Gastrointestinal cancer is a group of tumors that affect multiple sites of the digestive system, including the stomach, liver, colon and pancreas. These cancers are very aggressive and rapidly metastasize, thus identifying effective targets is crucial ...
Bacigalupo, Maria Lorena, Carabias, Pablo, Troncoso, María Fernanda   +2 more
core   +1 more source

Imaging for pancreatic ductal adenocarcinoma

Chinese Clinical Oncology, 2017
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers worldwide due to its aggressiveness and the challenge to early diagnosis. Complete surgical resection is the only curative option, but fewer than 20% of patients have potentially resectable disease at the time of the diagnosis.
Natally, Horvat, Davinia E, Ryan, Maria D, LaGratta, Pari M, Shah, Richard Kinh, Do   +4 more
openaire   +2 more sources

ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth [PDF]

, 2017
Pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer death; identifying PDAC enablers may reveal potential therapeutic targets. Expression of the actomyosin regulatory ROCK1 and ROCK2 kinases increased with tumor progression in human and ...
Anderson, Kurt I., Helbig, Lena, Julian, Linda, Kadir, Shereen, Kalna, Gabriela, McGhee, Ewan J., Morton, Jennifer P., Mullin, Margaret, Olson, Michael F., Pinho, Andreia V., Rath, Nicola, Rooman, Ilse, Samuel, Michael S.   +12 more
core   +1 more source

MicroRNAs in pancreatic ductal adenocarcinoma

World Journal of Gastroenterology, 2011
Ductal adenocarcinoma of the pancreas is a lethal cancer for which the only chance of long-term survival belongs to the patient with localized disease in whom a potentially curative resection can be done. Therefore, biomarkers for early detection and new therapeutic strategies are urgently needed.
Jong Y, Park, James, Helm, Domenico, Coppola, Donghwa, Kim, Mokenge, Malafa, Seung Joon, Kim   +5 more
openaire   +2 more sources

Photodynamic Therapy for Pancreatic Ductal Adenocarcinoma [PDF]

Cancers, 2021
Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal of human cancers. Clinical trials of various chemotherapy, radiotherapy, targeted agents and combination strategies have generally failed to provide meaningful improvement in survival for patients with unresectable disease.
Vida Karimnia, Frank J. Slack, Jonathan P. Celli   +2 more
openaire   +2 more sources

Expression and clinical significance of placenta-specific 1 in pancreatic ductal adenocarcinoma

Tumor Biology, 2017
The limited efficacy of conventional therapies for pancreatic ductal adenocarcinoma has led to the growing interest for identifying potential antigenic targets for immunotherapy.
Yin Yin, Xu Zhu, Shanshan Huang, Jiawei Zheng, Mengyun Zhang, Wencui Kong, Qun Chen, Yan Zhang, Xiong Chen, Kerong Lin, Xuenong Ouyang   +10 more
doaj   +1 more source

MiR-590 Suppresses Proliferation and Induces Apoptosis in Pancreatic Cancer by Targeting High Mobility Group A2

Technology in Cancer Research & Treatment, 2020
Background: Pancreatic ductal adenocarcinoma is a common malignancy with high morbidity. MicroRNAs have been demonstrated to be critical posttranscriptional regulators in tumorigenesis.
Ya-Dong Wang MD, Jia-Ding Mao PhD, Jun-Feng Wang MD, Mao-Qi Xu MD   +3 more
doaj   +1 more source

Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma [PDF]

, 2016
Immunotherapy approaches for pancreatic ductal adenocarcinoma (PDAC) have met with limited success. It has been postulated that a low mutation load may lead to a paucity of T cells within the tumor microenvironment (TME).
Alvarez, Hector A., Bailey, Peter, Biankin, Andrew V., Chang, David K., Chattopadhyay, Chandrani, Ekmekcioglu, Suhendan, Forget, Marie-Andrée, Grimm, Elizabeth A., Haymaker, Cara, Hwu, Patrick, Kim, Sun-Hee, Maitra, Anirban, Roszik, Jason, San Lucas, Francis A.   +13 more
core   +1 more source

A microenvironment-inspired synthetic 3D model for pancreatic ductal adenocarcinoma organoids

Nature Materials, 2021
Experimental in vitro models that capture pathophysiological characteristics of human tumours are essential for basic and translational cancer biology.
Christopher R. Below, Joanna Kelly, Alex T. Brown, J. Humphries, Colin Hutton, Jingshu Xu, Brian Y. Lee, C. Cintas, Xiaohong Zhang, Victor Hernandez-Gordillo, L. Stockdale, Matthew A Goldsworthy, Joe Geraghty, Lucy Foster, D. A. O’Reilly, Barbara Schedding, J. Askari, Jessica Burns, N. Hodson, Duncan L. Smith, C. Lally, G. Ashton, David Knight, Aleksandr Mironov, A. Banyard, J. Eble, J. Morton, M. Humphries, L. Griffith, Claus Jørgensen   +29 more
semanticscholar   +1 more source